

PRESS RELEASE

Epoqe Pharma receives funding!

- Lundbeckfonden has provided 5 million DKK (670K Euro) in a funding to Epoqe Pharma for the development of the peptide-based treatment for AMI.
- In addition, Innovationsfonden has provided 1.5 million DKK (200K Euro) in funding to support the development.

Copenhagen, July 7, 2023. Epoqe Pharma, a pre-clinical-stage biopharmaceutical company focused on the development of novel treatments for serious cardiovascular diseases, with the primary indication being Acute Myocardial Infarct (AMI), announces today that funding has been received from both Lundbeckfonden and Innovationsfonden, reflecting the growth and further development of Epoqe Pharma.

"We are grateful for the support and belief shown by both Lundbeckfonden and Innovationsfonden," says Anette Sams, Founder and CEO of Epoqe Pharma. "With this funding, we will be able to generate invaluable data that will direct our scientific translation and pave the way for improved treatments for patients worldwide."

Epoqe Pharmas research originates from collaborative research from Copenhagen University, Novo Nordisk and Copenhagen University Hospital. This research elucidated unique properties of specific peptides, offering a promising avenue for treating a wide range of cardiovascular diseases

NOTES FOR EDITORS

About Epoqe Pharma

Based in Copenhagen, Denmark, Epoqe Pharma is a pre-clinical stage biopharmaceutical company focused on the development of novel treatments for cardiovascular diseases. The company is currently developing a first-in-class therapy to treat Acute Myocardial Infarct, a serious, sudden heart indication.

About Acute Myocardial Infarct

Obstruction of the coronary blood flow during myocardial infarct limits oxygen supply to the heart muscle. This promotes cardiac ischemia, cardiac dysfunction and ischemic heart disease. Ischemic heart disease feeds into a cardiometabolic disease acceleration loop.

Ischemic heart disease is #1 global cause of death, disability and human suffering with costs of 11 bn\$ in 2017 (US only).

For further information, please contact:

Lasse Nørregaard, CBO
Email: Lasse@epoqepharma.com